Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Cullinan Therapeutics's CLN-049?
CLN-049 is a monoclonal antibody commercialized by Cullinan Therapeutics, with a leading Phase I program in Myelodysplastic Syndrome. According to...